PARP Inhibitors Display Differential Efficacy in Models of <i>BRCA</i> Mutant High-Grade Serous Ovarian Cancer

PARP Inhibitors Display Differential Efficacy in Models of <i>BRCA</i> Mutant High-Grade Serous Ovarian Cancer

Several poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors are now in clinical use for tumours with defects in BReast CAncer genes <i>BRCA1</i> or <i>BRCA2</i> that result in deficient homologous recombination repair (HRR). Use of olaparib, niraparib or rucapari...

Full description

Bibliographic Details
Main Authors: Kristie-Ann Dickson, Tao Xie, Christian Evenhuis, Yue Ma, Deborah J. Marsh
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:International Journal of Molecular Sciences
Subjects:
BRCA1
BRCA2
homologous recombination repair
PARP inhibitor
olaparib
rucaparib
Online Access:https://www.mdpi.com/1422-0067/22/16/8506

Internet

https://www.mdpi.com/1422-0067/22/16/8506

Similar Items